hotspot -WSS

hotspot

author：focus 2025-08-11 08:00:26 - browse：87

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Emergency workers more likely to restrain Black patients: study

hotspot

focus

WSS

CRISPR pioneers react to Casgevy, first gene

Hearing on Medicare drug price negotiation gets unusually heated

Does good food count as health care? Study aims to find out

FDA panel to weigh approval of NurOwn, controversial ALS drug

Ukraine and a new approach to mental health in war

Drug for rare kidney disease narrowly misses mark in clinical trial

leisure time

hotspot

focus

What does generative AI mean for health care? We asked experts

Congress must reauthorize a committee to support older Americans

Guidelines to prevent youth baseball injuries need more muscle

Second xenotransplant done with gene

Tori Bowie and the unacceptable rates of Black maternal death

Senate HELP committee spars over health care workforce policies

Activists slam private health insurers over coverage restrictions

Gain of function research would be limited under House proposal

As demand for Covid shots wanes, Moderna seeks its next success

Weight loss drug costs may need more research, senator suggests

explore

Biotech lab space demand falls sharply

Intarcia’s device

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Anthos stroke drug appears safer than common blood thinner

PBM reforms clear House panel

Hospitals look to new technology to keep health care workers safe

explore

hotspot

focus

focus